References
- JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin200959422524919474385
- MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
- MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
- TanakaTMatsuokaMSutaniASpanish Lung Cancer Group. Frequency of and variables associated with the EGFR mutation and its subtypesInt J Cancer2010126365165519609951
- WenMMWangXJSunYDetection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancerOnco Targets Ther201691989199527103824
- ShiYKLiJLZhangSCMolecular Epidemiology of EGFR Mutation Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER StudyPLoS One20151011e014351526599344
- LeeCKWuYLDingPNImpact of Specific Epidermal Growth Factor Receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysisClin Oncol2015331719581965
- WangSWangZEGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysisInt J Clin Exp Med2014781967197825232377
- XuJZhangYJinBEfficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in ChinaJ Cancer Res Clin Oncol201614261325133026942444
- ChoSHParkLCJiJHEfficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutationCancer Chemother Pharmacol201270231532022760226
- LiuYRenZWangJEpidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: systematic review and meta analysisThorac Cancer20167440641427385982
- FangWZhangJLiangWLEfficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutationJ Thorac Dis20135558559224255770
- WenMWangXSunYDetection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancerOnco Targets Ther201691989199527103824
- ZhangQZhuLZhangJEpidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patientsBMC Cancer2015158825886585
- EnewoldLThomasAReal-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United StatesPLoS One2016116e015672827294665
- ShukuyaTTakahashiTKairaREfficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reportsCancer Sci201110251032103721272159
- ZengZChenHJYanHHSensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutationsInt J Biol Markers20133249258